BridgeBio Oncology Therapeutics, Inc. (BBOT) awarded inducement grants to two new employees to support their work on RAS-pathway malignancies. The employees received non-qualified stock options for 65,350 shares of BBOT common stock, with an exercise price of $10.84 per share. The grants will vest over time, subject to continued service with the company. These inducement grants were given outside of BBOT’s equity incentive plans and were approved by the compensation committee of the board of directors. BBOT is focused on developing small molecule therapeutics to target RAS and PI3Kα malignancies. For more information, visit www.bbotx.com.

Read more at GlobeNewswire: BridgeBio Oncology Therapeutics Reports Inducement Grants